Form 8-K - Current report:
SEC Accession No. 0001739410-25-000021
Filing Date
2025-02-25
Accepted
2025-02-25 16:41:21
Documents
13
Period of Report
2025-02-24
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K rlyb-20250224.htm   iXBRL 8-K 26194
  Complete submission text file 0001739410-25-000021.txt   156878

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rlyb-20250224.xsd EX-101.SCH 1773
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rlyb-20250224_lab.xml EX-101.LAB 23449
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rlyb-20250224_pre.xml EX-101.PRE 13575
15 EXTRACTED XBRL INSTANCE DOCUMENT rlyb-20250224_htm.xml XML 2917
Mailing Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510
Business Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510 203- 859-3820
Rallybio Corp (Filer) CIK: 0001739410 (see all company filings)

EIN.: 851083789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40693 | Film No.: 25664172
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)